Sensus Healthcare (NASDAQ:SRTS) Director Buys $129,127.28 in Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta acquired 37,537 shares of Sensus Healthcare stock in a transaction on Friday, August 28th. The stock was purchased at an average cost of $3.44 per share, with a total value of $129,127.28. Following the purchase, the director directly owned 267,480 shares of the company’s stock, valued at approximately $920,131.20. This trade represents a 16.32% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Eric Sachetta also recently made the following trade(s):

• On Monday, August 31st, Eric Sachetta acquired 27,304 shares of Sensus Healthcare stock. The shares were purchased at an average price of $3.54 per share, with a total value of $96,656.16.
• On Thursday, August 27th, Eric Sachetta bought 10,925 shares of Sensus Healthcare stock. The shares were purchased at an average cost of $3.18 per share, for a total transaction of $34,741.50.
• On Wednesday, August 26th, Eric Sachetta bought 9,708 shares of Sensus Healthcare stock. The stock was purchased at an average price of $3.29 per share, for a total transaction of $31,939.32.
• On Monday, August 24th, Eric Sachetta purchased 34,697 shares of Sensus Healthcare stock. The stock was acquired at an average cost of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Trading Down 2.4%

Shares of SRTS stock opened at $3.25 on Thursday. The firm has a fifty day simple moving average of $3.08 and a two-hundred day simple moving average of $3.49. Sensus Healthcare, Inc. has a 12 month low of $2.66 and a 12 month high of $5.49. The firm has a market capitalization of $53.49 million, a PE ratio of -3.46 and a beta of 1.13.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.60 million. Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Alliance Global Partners reissued a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Lake Street Capital cut their target price on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Wall Street Zen downgraded Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings lowered Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.83.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds have recently modified their holdings of the company. EP Wealth Advisors LLC purchased a new position in shares of Sensus Healthcare in the 2nd quarter worth approximately $49,000. XTX Topco Ltd bought a new stake in Sensus Healthcare during the fourth quarter worth $77,000. Jane Street Group LLC bought a new position in Sensus Healthcare in the 4th quarter valued at $79,000. Ingalls & Snyder LLC purchased a new stake in shares of Sensus Healthcare during the 4th quarter valued at $219,000. Finally, BlackRock Inc. bought a new stake in shares of Sensus Healthcare during the 2nd quarter worth $252,000. Institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.